Two Firms Prep Pivotal Trials For Devices To Prevent Kidney Injury In The Cath Lab
This article was originally published in The Gray Sheet
Executive SummaryContrast agents are fundamental tools for diagnostic and interventional cath lab procedures, but they come with the risk of acute kidney damage.
You may also be interested in...
Rep. Leonard Lance reintroduced a bill in the House to address flaws in Medicare’s reimbursement system for diagnostics. Guided Therapeutics receives more questions from FDA on the PMA for its LuViva cervical scan. Study news from InSightec, Direct Flow Medical and PLC Systems. More news.
Interventional cardiologists presented new data at the annual meeting of The Society for Cardiovascular Angiography and Interventions supporting the safe use of live video transmission of transcatheter aortic valve replacement cases, and results from other late-breaking clinical trials.
Osprey Medical plans IPO. ViewRay raises $45 million. More financings.